IP Library Granted Patent US 7,618,792
Granted Patent B2
US 7,618,792 · App. 11/327,589 · Granted Nov 17, 2009

Multiplexed detection of anti-red cell alloantibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,618,792
App. No.
11/327,589
Granted
Nov 17, 2009
Kind
B2
Abstract

Disclosed are methods for detecting antibody in a sample, where the antibody targets an antigen expressed by red blood cells or red blood cell ghosts. Rather than detecting the binding events between a particular antigen antibody pair (as in traditional agglutination based assays) the methods herein allow for multiplexed detection of clinically important allo-immune antibodies to blood group antigens. Specifically the method involves generating fluorescently encoded red blood cells or red blood cell ghosts with known antigen presentation and using them to detect the presence of antibody in serum/plasma with a fluorescent sandwich type immunoassay. The assay results can be read using flow cytometric or fluorescent microscope based imaging techniques.

Claims (13)

1. A method for detecting and identifying alloantibodies in a blood sample, comprising:

generating a set of several differently encoded red blood cells or red blood cell ghosts displaying antigens on the cell surface whose identities are known, such that differently encoded red blood cells or red blood cell ghosts in the set are antigenically distinct from other red blood cells or red blood cell ghosts in the set;

wherein said differently encoded cells or ghosts contain two or more fluorescent dyes mixed at different predetermined ratios which upon excitation exhibit distinct fluorescent emission signals, wherein the ratio of the fluorescent emission signals is governed by said predetermined ratio and wherein the presence of the fluorescent dye does not substantially alter the antigenicity of the cells or ghosts;

contacting said set with said blood sample under conditions permitting binding of said alloantibodies present in the sample to the antigens on the cell surface;

removing the excess blood sample components from contact with the set thereby leaving alloantibody bound to the antigens on the cell surface;

detecting the presence of the bound alloantibody on red blood cells or red blood cell ghosts using a labeled secondary antibody that binds to alloantibodies captured by the red blood cells or red blood cell ghosts by determining the presence of signals from the labeled secondary antibody;

determining the ratio of fluorescent encoding signals associated with different red blood cells or red blood cell ghosts; and

correlating the signals from the labeled secondary antibody with the ratio of fluorescent encoding signal for red blood cells or red blood cell ghosts; and

determining the identity of the alloantibody.

2. The method of claim 1 wherein the secondary antibody is labeled with a fluorescent dye.

3. The method of claim 1 wherein the secondary antibody is monoclonal.

4. The method of claim 1 wherein the detecting step is performed with flow cytometry or by imaging an array of the encoded cells or ghosts, imaging the bound secondary antibodies and correlating the position of the labeled secondary antibodies that bound with the array image to determine which cells or ghosts in the set bound to alloantibodies in the sample.

5. The method of claim 1 wherein the blood sample is serum blood or plasma.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Mar 15, 2023
From: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS, INC.
Reel/Frame 063090/0111 →
RELEASE OF SECURITY INTEREST Recorded Mar 15, 2023
From: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS, INC.
Reel/Frame 063090/0033 →
SECURITY INTEREST Recorded Jul 2, 2020
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS INC.
To: ALTER DOMUS (US) LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 053119/0152 →
SECURITY INTEREST Recorded Jul 2, 2020
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 053119/0135 →
RELEASE OF PATENT SECURITY INTERESTS Recorded Jul 2, 2020
From: CITIBANK, N.A.
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; IMMUCOR GTI DIAGNOSTICS, INC.; SIRONA GENONICS, INC.
Reel/Frame 053121/0935 →
PATENT SECURITY AGREEMENT Recorded Aug 19, 2011
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026778/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2010
From: BANERJEE, SUKANTA
To: BIOARRAY SOLUTIONS LTD.,
Reel/Frame 024599/0098 →